Physician profile
April Wamsley
NPI 1578802740
$915.46
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $460 · 2022: $209 · 2023: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $119.58 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $102.10 | 2021-2023 | Breztri |
| Novo Nordisk INC | $83.93 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $65.37 | 2021 | |
| Abbvie INC. | $62.95 | 2021-2023 | |
| Pfizer INC. | $58.38 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $57.29 | 2021-2022 | |
| Gilead Sciences, INC. | $50.89 | 2023 | |
| Mylan Specialty L.P. | $47.44 | 2022-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $43.42 | 2022-2023 | Abilify Maintena, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.25 | 2021-2023 | Jardiance |
| Organon LLC | $22.34 | 2023 | Nexplanon |
| Janssen Biotech, INC. | $20.37 | 2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $19.51 | 2021 | |
| Clarus Therapeutics INC. | $18.42 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17.74 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.98 | 2023 | Belbuca |
| Glaxosmithkline, LLC. | $15.40 | 2023 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2021 | |
| Genentech USA, INC. | $12.51 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.36 | 2021 | |
| Biodelivery Sciences International, INC. | $11.39 | 2021 | |
| Merck Sharp & Dohme LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Wamsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.